{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T18:05:22Z","timestamp":1762625122156,"version":"3.41.2"},"reference-count":34,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Cardiology"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Sacubitril\u2010valsartan, an inhibitor of the angiotensin receptor neprilysin (ARNi), has been purported to exhibit superiority over angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) in individuals diagnosed with heart failure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Hypothesis<\/jats:title><jats:p>This paper gives an updated meta\u2010analysis comparing the efficacy and safety of sacubitril\u2010valsartan to that of standard treatment for different types of heart failure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The meta\u2010analysis comprised a total of nine randomized controlled trials (RCTs), incorporating data from a substantial sample size of 15\u2009939 patients. The study observed a decrease in overall mortality and mortality related to cardiovascular causes among patients in the heart failure with reduced ejection fraction (HFrEF) category who were treated with sacubitril\u2010valsartan. However, no statistically significant variation in this outcome was seen among patients with heart failure with preserved ejection fraction and HFmrEF. Patients who were administered sacubitril\u2010valsartan had a notably elevated likelihood of experiencing hypotension. Nevertheless, no significant disparities were observed in terms of other adverse events among the various treatment groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Current meta\u2010analysis provide support for use of sacubitril\u2010valsartan in decreasing mortality in patients with HFrEF. However, more numbers of studies are required to draw a definite conclusion on other benefits associated with sacubitril\u2010valsartan use over standard treatment of ACE inhibitors and ARBs.<\/jats:p><\/jats:sec>","DOI":"10.1002\/clc.24192","type":"journal-article","created":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T07:07:50Z","timestamp":1701155270000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A meta\u2010analysis investigating the efficacy and adverse events linked to sacubitril\u2010valsartan in various heart failure subtypes"],"prefix":"10.1002","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4170-8522","authenticated-orcid":false,"given":"Qing","family":"Ji","sequence":"first","affiliation":[{"name":"Nursing College Zibo Vocational Institute Zibo Shandong China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,11,27]]},"reference":[{"key":"e_1_2_9_2_1","first-page":"1161","article-title":"Diagnosis and evaluation of heart failure","volume":"85","author":"King M","year":"2012","journal-title":"Am Fam Physician"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1858"},{"volume-title":"StatsPearl","year":"2021","author":"Hajouli S","key":"e_1_2_9_4_1"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1161\/HHF.0b013e318291329a"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000659"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200826060-00001"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-018-0815-3"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2013.12.028"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-020-00952-0"},{"key":"e_1_2_9_11_1","article-title":"Universal definition and classification of heart failure: a step in the right direction from failure to function","volume":"13","author":"Gibson G","year":"2021","journal-title":"Am Coll Cardio Jul"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2006.089656"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.014240"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2016-134045"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccl.2013.09.002"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/08998280.2003.11927893"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.16667"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41540-017-0013-4"},{"volume-title":"StatPearls","year":"2021","author":"Nicolas D","key":"e_1_2_9_19_1"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409077"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.026407"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad344"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(19)31456-1"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.12843"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2076"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-20-0854"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908655"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61227-6"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812851"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.037077"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.044586"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1159\/000507327"},{"volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (Updated February 2022)","year":"2023","author":"Higgins JPT","key":"e_1_2_9_35_1"}],"container-title":["Clinical Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clc.24192","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T10:10:44Z","timestamp":1713175844000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/clc.24192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,27]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1002\/clc.24192"],"URL":"https:\/\/doi.org\/10.1002\/clc.24192","archive":["Portico"],"relation":{},"ISSN":["0160-9289","1932-8737"],"issn-type":[{"type":"print","value":"0160-9289"},{"type":"electronic","value":"1932-8737"}],"subject":[],"published":{"date-parts":[[2023,11,27]]},"assertion":[{"value":"2023-10-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e24192"}}